Łuszczki Edyta, Mazur Artur, Gwóźdź W., Reisch L., Eiben G., Hunsberger M., Konstabel K., Kovacs E., Mendl E., Saamel M., Wolters M., The effect of smileys as motivational incentives on children's fruit and vegetable choice, consumption and waste : A field experiment in schools in five European countries [w:]Food Policy, 2020, p-ISSN: 0306-9192      200pkt.

Abstract

To assess whether smiley stamps work as a motivational incentive to promote fruit and vegetable eating among children, we conducted a field experiment in ten primary schools in five European countries using one control and one treatment school per country. The six-week experiment was split into three two-week phases before, during and after the smiley was implemented. During the smiley phase, the children received a smiley stamp for choosing a portion of fruits or vegetables. We find an increase attributed to the smiley stamp on children’s fruit and vegetable choice and consumption, but also waste. Comparing the effects across countries, we observe significant variations in the smiley effect. This study thus demonstrates, in general, that a low-cost, easy-to-implement incentive such as a smiley stamp has the potential to motivate school children to increase their fruit and vegetable consumption; the study simultaneously underscores the high relevance of context for the effects of incentives.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

Reich Adam, Ständer Sonja, Yosipovitch Gil, Legat Franz J., Lacour Jean-Philippe, Paul Carle, Narbutt Joanna, Bieber Thomas, Misery Laurent, Wollenberg A., Andrzej, Ahmad Faiz, Piketty Christophe, Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis [w:] New England Journal of Medicine,  2020 : Vol. 382, s. 706-716,  p-ISSN: 0028-4793   200pkt.

Abstract

Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

Bartosik-Psujek Halina,  Hauser Stephen L., Bar-Or Amit, Cohen Jeffrey A., Comi Giancarlo, Correale Jorge, Coyle Patricia K., Cross Anne H., De Seze Jerome, Leppert David, Montalban Xavier, Selmaj Krzysztof, Wiendl Heinz, Kerloeguen Cecile, Willi Roman, Li Bingbing, Kakarieka Algirdas, Tomic Davorka, Goodyear Alexandra, Pingili Ratnakar, Haring Dieter A., Ramanathan Krishnan, Merschhemke Martin, Kappos Ludwig, Ofatumumab versus Teriflunomide in Multiple Sclerosis [w:] New England Journal of Medicine, 2020 : Vol. 383, iss. 6, s. 546-557 p-ISSN: 0028-4793     200pkt.

Abstract

Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

 Markiewicz Mirosław Marian, Beelen Dietrich Wilhelm, Trenschel Rudolf, Stelljes Matthias, Groth Christoph, Masszi Tamás, Reményi Péter, Wagner-Drouet Eva-Maria, Hauptrock Beate, Dreger Peter,  Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L) : a randomised, non-inferiority, phase 3 trial [w:] Lancet Haematology, 2020 : Vol. 7, Iss. 1, p. E28-E39, p-ISSN: 2352-3026   200pkt.

Abstract

Further improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of older or comorbid patients with acute myeloid leukaemia or myelodysplastic syndrome. We aimed to evaluate the efficacy and safety of conditioning with treosulfan plus fludarabine compared with reduced-intensity busulfan plus fludarabine in this population.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

Baran Joanna, Dereń Katarzyna, Łuszczki Edyta, Mazur Artur, Sobek Grzegorz, Weres Aneta, Rodriguez-Martinez Andrea, Zhou Bin, Sophiea Marisa K., Bentham James, Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories : a pooled analysis of 2181 population-based studies with 65 million participants [w:]Lancet,  2020 : Vol. 396, nr 10261, s. 1511-1524, p-ISSN: 0140-6736    200pkt.

Abstract

Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

Korczowski Bartosz, Wolf Joshua, Kalocsai Krisztina, Fortuny Claudia, Lazar Stefan, Bosis Samantha, Petit Arnaud, Bradford Daniel, Cross-Dabrera Rodney, Incera Elodie, Melis Joost, Maanen van Rob., Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection : A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE) [w:]  Clinical Infectious Diseases, 2020 : Vol. 71, iss. 10, p. 2581-2588, p-ISSN: 1058-4838 200pkt.

 Abstract

Fidaxomicin, a narrow-spectrum antibiotic approved for Clostridioides (Clostridium) difficile infection (CDI) in adults, is associated with lower rates of recurrence than vancomycin; however, pediatric data are limited. This multicenter, investigator-blind, phase 3, parallel-group trial assessed the safety and efficacy of fidaxomicin in children.

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………